Skip to main content

Female DVIU and Urethral Dilation

Urethral dilation is an option for a confirmed female urethral stricture (FUS). Female DVIU lacks a reliable dedicated outcomes evidence base and should not be described as interchangeable with dilation by importing male-stricture recommendations.[1][12]

For the male counterpart, see DVIU and Urethral Dilation. For paclitaxel-enhanced endoscopic treatment, see Drug-Coated Balloon Therapy.

Guideline Position​

AUA guidance favors reconstructive options for women given the low efficacy of endoscopic treatment. EAU guidance permits initial dilation and distinguishes maintenance dilation from definitive cure.[1][12]

ScenarioFemale-specific guidance
Initial confirmed FUSDilation to 24–41 Fr is an EAU option (weak recommendation).
First recurrenceRepeat dilation with planned weekly 16–18 Fr self-dilation may maintain patency.
Second recurrence, unable to self-dilate or seeking definitive treatmentOffer urethroplasty.
Isolated short meatal strictureMeatoplasty is an option.

The EAU recurrence pathway is not a requirement to postpone reconstruction in a woman choosing definitive treatment after counseling.[1][12]

Why Female Strictures Are Different​

FUS is rare — affecting roughly 4–20% of women evaluated for refractory LUTS-related bladder outlet obstruction.[2] Evidence is largely observational, with heterogeneous diagnostic and outcome definitions; small comparative trials do not settle the optimal technique.[2][3]

Etiology is frequently idiopathic; iatrogenic injury from instrumentation or prior surgery is also important. Other causes include obstetric trauma (especially cephalopelvic disproportion), pelvic trauma, malignancy, radiation, urethral / vaginal atrophy, recurrent infection, and dermatologic disease (lichen planus, lichen sclerosus).[1]

Diagnosis is challenging given the non-specific presentation. Patients may report obstructive LUTS, recurrent UTI, hesitancy, weak stream, urgency-frequency, urethral pain, elevated PVR, or acute retention. Inability to pass even a small catheter is suggestive. VCUG demonstrates the entire female urethra well; cystourethroscopy confirms the stricture.[1]

Anatomic constraints unique to the female urethra:

  • Short urethral length (~ 4 cm) — leaves less margin between the stricture and the sphincteric complex, raising the risk of de novo SUI with aggressive incision or dilation.
  • A short stricture does not by itself establish that female DVIU is preferable to dilation or reconstruction.
  • The risk-benefit balance for endoscopy is therefore narrower than in men.

Urethral Dilation​

Dilation is the most commonly performed first-line endoscopic intervention for FUS, often attempted at least once before considering urethroplasty.[3][4]

Technique — sequential calibrated dilators (sounds or balloon dilators) progressively enlarge the lumen, with the intended caliber chosen from the female-specific guideline range above, performed in clinic or under anesthesia.

Outcomes — long-term success is consistently poor across systematic reviews:

Series / ReviewnMean follow-upPooled / reported success
Osman 2013 SR[5]aggregated32–43 mo~ 47%
Sarin 2021 SR / meta[6]aggregatedcomparable41–49% pooled
Chakraborty 2022 review[4]aggregatedcomparable41–49%
Blaivas 2012[7]17 (initial dilation)—6% durable success (16 / 17 recurred)
Bouchard 2025 review[3]aggregated—efficacy decreases with each subsequent dilation

Female DVIU​

DVIU involves endoscopic scar incision. Published female incision patterns vary, and robust comparative evidence does not establish a preferred direction or equivalence to dilation.[12]

Technical considerations specific to the female urethra:

  • The short urethra means even a "short" incision approaches the sphincter; incise conservatively.
  • For isolated meatal disease, consider meatoplasty rather than assuming DVIU is the preferred procedure.
  • Standalone female-DVIU outcome data are scarce — most series pool DVIU with dilation under "endoscopic management."[2][5][8]

Endoscopic Management vs Urethroplasty​

Observational series generally report higher patency after urethroplasty than dilation. These pooled rates are not randomized comparisons and differ in follow-up and definitions:

TechniquePooled successMean follow-up
Urethral dilation / DVIU41–49%32–43 mo[4][5][6]
Vaginal flap urethroplasty91–93%32–42 mo[4][5][6]
Buccal mucosa graft urethroplasty89–94%15–19 mo[5][6]
Vaginal free graft urethroplasty80–87%15–22 mo[5][6]

The consensus across the literature is that urethroplasty should not be delayed after failure or short-interval recurrence following dilation or DVIU; most experts recommend proceeding to urethroplasty after one or at most two failed endoscopic attempts.[3][4][8]

Drug-Coated Balloon — Where the Female Evidence Stands​

Optilume drug-coated balloon (DCB) is FDA-approved for anterior urethral stricture in men. The female evidence base is very small and very poor — currently two case reports plus a single 12-patient single-center conference abstract. Use should be considered exploratory and individualized; counsel accordingly.[9][10][11]

Complications and Adjuncts​

  • Recurrence is the dominant complication; risk rises with each repeat endoscopic attempt.
  • De novo SUI is the major procedure-specific concern, particularly with aggressive dilation or DVIU near the sphincter; reported more commonly after open urethroplasty (~ 9.4% mild-to-moderate, most responsive to PFPT) than after endoscopic treatment.[3]
  • Other complications: urethral bleeding, false passage, worsening peri-urethral fibrosis. Repeat instrumentation itself is a recognized cause of stricture progression.[1]
  • Self-dilation adjunct — discuss ongoing catheterization burden and distinguish maintained patency from cure; use the female-specific recurrence pathway above.[1]
  • Intralesional injection of mitomycin C or corticosteroids at the time of DVIU has been described, with limited evidence in females.[1]

Summary​

Confirm an anatomical stricture before intervention. Counsel about dilation's limited durability, self-dilation as maintenance, and urethroplasty as a definitive option. Female DVIU should not inherit male trial results or guideline grades.[1][3][4][5][6][8]

References​

1. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. Urethral stricture disease guideline amendment (2023). J Urol. 2023;210(1):64-71. doi:10.1097/JU.0000000000003482.

2. Turchi B, Lumen N, Verla W, Waterloos M. Female urethral stricture disease: a narrative review on diagnosis, surgical techniques and outcomes. Int J Impot Res. 2026;38(4):286-295. doi:10.1038/s41443-025-01079-6.

3. Bouchard B, Campeau L. Surgery for female urethral stricture. Neurourol Urodyn. 2025;44(1):51-62. doi:10.1002/nau.25358.

4. Chakraborty JN, Chawla A, Vyas N. Surgical interventions in female urethral strictures: a comprehensive literature review. Int Urogynecol J. 2022;33(3):459-485. doi:10.1007/s00192-021-04906-8.

5. Osman NI, Mangera A, Chapple CR. A systematic review of surgical techniques used in the treatment of female urethral stricture. Eur Urol. 2013;64(6):965-973. doi:10.1016/j.eururo.2013.07.038.

6. Sarin I, Narain TA, Panwar VK, et al. Deciphering the enigma of female urethral strictures: a systematic review and meta-analysis of management modalities. Neurourol Urodyn. 2021;40(1):65-79. doi:10.1002/nau.24584.

7. Blaivas JG, Santos JA, Tsui JF, et al. Management of urethral stricture in women. J Urol. 2012;188(5):1778-1782. doi:10.1016/j.juro.2012.07.042.

8. Waterloos M, Verla W. Female urethroplasty: a practical guide emphasizing diagnosis and surgical treatment of female urethral stricture disease. Biomed Res Int. 2019;2019:6715257. doi:10.1155/2019/6715257.

9. Stuehmeier J, Jelisejevas LA, Kink P, Gulacsi A, Horninger W, Rehder P. Optilume drug-coated balloon dilation in complex female urethral stricture. Urol Case Rep. 2021;41:101987. doi:10.1016/j.eucr.2021.101987.

10. Jelisejevas LA, Tulchiner G, Stuehmeier J, et al. PD05-02 Optilume drug-coated balloon dilation in the treatment of female urethral stricture disease. J Urol. 2025;213(5S):e108. doi:10.1097/01.JU.0001109760.63452.97.02.

11. Thomas HS, Stern N, Neu S, Herschorn S. Drug-coated balloon dilation for female urethral stricture. Urol Case Rep. 2025;59:102985. doi:10.1016/j.eucr.2025.102985.

12. European Association of Urology. Urethral Strictures: Disease Management in Females. 2026. Official guideline.